EGL ( EAGL) was climbing higher after main shareholder and CEO James Crane renewed his $36-a-share bid to take the freight company private, this time leading a group consisting of Centerbridge Partners and The Woodbridge Co. Earlier this month shares of the Houston-based firm plunged after General Atlantic, Crane's former partner in the buyout offer, backed out in a reaction to soft fourth-quarter guidance. EGL also officially issued those weak numbers -- income of $10.9 million, or 27 cents a share, compared with $19.1 million, or 47 cents a share, last year. But EGL shares were rising $1.89, or 5.7%, to $35.36. Novatel Wireless ( NVTL) said after the market close Tuesday that fourth-quarter non-GAAP profits rose to $4.4 million, or 14 cents a share, up from break-even last year. Revenue surged 58% to $77 million. The Street expected income at 6 cents a share on $76.1 million sales. The San Diego-based wireless-equipment maker was gaining 50 cents, or 3.9%, to $13.26. Syniverse ( SVR), which sells services to the wireless-telecom industry, slid on dwindling profits. The Tampa, Fla., company posted adjusted fourth-quarter income of $11.5 million, or 17 cents a share, on sales that inched up 2.7% from last year to $85.8 million. Year-ago income came to $14.8 million, or 22 cents a share. Analysts were seeking 24 cents a share on $85.1 million in revenue. Looking ahead, Syniverse expects 2007 sales of between $325 million and $335 million, at least $23 million under expectations. Shares were falling $2.17, or 15.5%, to $11.87.
Avanir Pharma ( AVNR) dropped on word it needs to provide the Food and Drug Administration with additional data supporting a lower-dosage formulation of Zenvia, its treatment for involuntary emotional expression disorder, a condition that can arise from a wide array of neurological diseases. The Aliso Viejo, Calif., company expects this will take about two years. Shares were losing 35 cents, or 15.6%, to $1.89. PRA International ( PRAI) said earnings sank to $5.7 million, or 23 cents a share, including stock-option expenses and a one-off $1.7 million charge related to the resignation of CEO Patrick Donnelly. Last year the Reston, Va.-based company, which manages clinical trials and other research for biotechs and pharmaceuticals, earned $7.5 million, or 31 cents a share. Analysts projected per-share income at 29 cents. Sales totaled $92.5 million compared with $76.5 million a year ago, which tops the $81.7 million average estimate. Shares were shedding $3.06, or 13.3%, to $19.99. Traffix ( TRFX) said earnings for the quarter ended Nov. 30 totaled only about $1,000, or break-even a share, compared with last year's gains of $781,000, or 5 cents a share. Revenue rose 3% year over year to $17.2 million, missing the $18.9 million called for by two analysts. Shares were dropping 73 cents, or 12.2%, to $5.25.
Salix Pharma ( SLXP) retreated after the Morrisville, N.C.-based company bought Merck's ( MRK) rights to gastrointestinal treatments Pepcid and Diuril for $55 million, plus $6 million in possible milestone fees. The company also said it borrowed $15 million on closing a new $100 million revolving credit facility last week. Despite better-than-expected fourth-quarter earnings of 29 cents a share, which reverses a 6-cent loss last year, Salix was off 85 cents, or 5.6%, to $14.25. Merck was recently up 86 cents, or 2%, to $44.04. Audible ( ADBL), maker of digital spoken-word versions of books and other media, soared 21% on
impressive fourth-quarter results. The Wayne, N.J.-based company narrowed its loss to $700,000, or 3 cents a share, compared with a year-ago loss of $2.2 million, or 9 cents a share. Wall Street was looking for a loss of 7 cents a share, according to Thomson Financial. Sales were also up 27.6% year over year to $23.3 million. Shares were adding $1.67 to $9.62. Construction company Dycom Industries ( DY) climbed after seeing 40% higher fourth-quarter income to 14 cents a share, or $5.6 million, which edges past estimates by a penny. Revenue, at $258.3 million, just topped the consensus estimate. Shares of the Florida-based company were up $2.52, or 11.5%, to $24.38.